Abstract:C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are two rare diseases caused by dysregulated activity of the alternative pathway of complement secondary to the presence of genetic and/or acquired factors. Complement factor I (FI) is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46). Because altered FI activity is causally related to the pathogenesis of C3G and aHUS, we sought to test functional activity of select CFI missense variants in these two patient cohorts. We identified 65 patients (16, C3G; 48, aHUS; 1 with both) with at least one rare variant in CFI (defined as a MAF < 0.1%). Eight C3G and eleven aHUS patients also carried rare variants in either another complement gene, ADAMTS13 or THBD . We performed comprehensive complement analyses including biomarker profiling, pathway activity and autoantibody testing, and developed a novel FI functional assay, which we completed on 40 patients. Seventy-eight percent of rare CFI variants (31/40) were associated with FI protein levels below the 25 th percentile; in 22 cases, FI levels were below the lower limit of normal (type 1 variants). Of the remaining nine variants, which associated with normal FI levels, two variants reduced FI activity (type 2 variants). No patients carried currently known autoantibodies (including FH autoantibodies and nephritic factors). We noted that while rare variants in CFI predispose to complement-mediated diseases, phenotypes are strongly contingent on the associated genetic background. As a general rule, in isolation, a rare CFI variant most frequently leads to aHUS, with the co-inheritance of a CD46 loss-of-function variant driving the onset of aHUS to the younger age group. In comparison, co-inheritance of a gain-of-function variant in C3 alters the phenotype to C3G. Defects in CFH (variants or fusion genes) are seen with both C3G and aHUS. This variability underscores the complexity and multifactorial nature of these two complement-mediated renal diseases.

A Novel Mutation in Complement 2 Accompanied by Susceptibility Variants in C3 Glomerulonephritis: A Case Study.

Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report.

Genetic Analysis of the Complement Pathway in C3 Glomerulopathy

[Complement System Regulation and C3 Glomerulopathy].

A haplotype in CFH family genes confers high risk of rare glomerular nephropathies

Combination of a Novel Genetic Variant in CFB Gene and a Pathogenic Variant in COL4A5 Gene in a Sibling Renal Disease: A Case Report

Co-existence of Alport syndrome and C3 glomerulonephritis in a proband with family history

Evaluation of the Significance of Complement-Related Genes Mutations in Atypical Postinfectious Glomerulonephritis: a Pilot Study

C3 glomerulopathy — understanding a rare complement-driven renal disease

C3 Glomerulonephritis:Clinicopathologic Analysis of 17 Cases

Clinical and pathological features of 52 patients with glomerulonephritis with dominant C3.

The Difficulties of Treating Complement-3–Mediated Glomerulopathy

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study

Complement Factor I Variants in Complement-Mediated Renal Diseases

Mutations of C3 in Atypical Hemolytic Uremic Syndrome (aHUS)

C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic

A Retrospective Analysis of Clinicopathology and Plasma Complement Activation in C3 Glomerulonephritis

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation

Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies

Monoclonal Immunoglobulin Mediates Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulonephritis